CANbridge Pharmaceuticals (HKG:1228) served a notice of termination of its exclusive UMass license agreement with the University of Massachusetts.
The company is also actively negotiating the terms to cancel its lease of the group's office and laboratory space in Boston under its downsizing plan, a Friday Hong Kong bourse filing said.
Under the UMass license agreement, the company obtained global rights to develop, manufacture, and commercialize a certain spinal muscular atrophy-treating gene therapy in Jan. 2023. The termination will take effect within 60 days from the notice date.
The biopharmaceutical company's shares closed nearly 4% lower on Friday.
Price (HKD): $0.24, Change: $-0.0090, Percent Change: -3.60%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。